JP2023534292A5 - - Google Patents

Info

Publication number
JP2023534292A5
JP2023534292A5 JP2023503070A JP2023503070A JP2023534292A5 JP 2023534292 A5 JP2023534292 A5 JP 2023534292A5 JP 2023503070 A JP2023503070 A JP 2023503070A JP 2023503070 A JP2023503070 A JP 2023503070A JP 2023534292 A5 JP2023534292 A5 JP 2023534292A5
Authority
JP
Japan
Prior art keywords
drug
cancer
immune complex
showed
jimt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023503070A
Other languages
English (en)
Japanese (ja)
Other versions
JP7660186B2 (ja
JP2023534292A (ja
Filing date
Publication date
Priority claimed from KR1020210060721A external-priority patent/KR102349925B1/ko
Application filed filed Critical
Publication of JP2023534292A publication Critical patent/JP2023534292A/ja
Publication of JP2023534292A5 publication Critical patent/JP2023534292A5/ja
Application granted granted Critical
Publication of JP7660186B2 publication Critical patent/JP7660186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023503070A 2020-07-16 2021-07-16 Fl118薬物が酸感受性リンカーに結合された複合体及びそれを用いた免疫複合体 Active JP7660186B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2020-0088005 2020-07-16
KR20200088005 2020-07-16
KR1020210060721A KR102349925B1 (ko) 2020-07-16 2021-05-11 Fl118 약물을 포함하는 화합물 및 이를 이용한 면역접합체
KR10-2021-0060721 2021-05-11
PCT/KR2021/009204 WO2022015110A1 (ko) 2020-07-16 2021-07-16 Fl118 약물이 산 민감성 링커에 연결된 접합체 및 이를 이용한 면역접합체

Publications (3)

Publication Number Publication Date
JP2023534292A JP2023534292A (ja) 2023-08-08
JP2023534292A5 true JP2023534292A5 (cg-RX-API-DMAC7.html) 2023-09-28
JP7660186B2 JP7660186B2 (ja) 2025-04-10

Family

ID=79339522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503070A Active JP7660186B2 (ja) 2020-07-16 2021-07-16 Fl118薬物が酸感受性リンカーに結合された複合体及びそれを用いた免疫複合体

Country Status (8)

Country Link
US (1) US20230270867A1 (cg-RX-API-DMAC7.html)
EP (1) EP4183418A4 (cg-RX-API-DMAC7.html)
JP (1) JP7660186B2 (cg-RX-API-DMAC7.html)
KR (3) KR102349925B1 (cg-RX-API-DMAC7.html)
CN (1) CN116075321A (cg-RX-API-DMAC7.html)
AU (1) AU2021308834A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189462A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022015110A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214849A1 (ko) * 2022-05-04 2023-11-09 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신계 약물이 산 민감성 링커에 연결된 접합체 및 이를 이용한 면역접합체
KR20240008280A (ko) * 2022-07-11 2024-01-18 주식회사 피노바이오 Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
JP2025529237A (ja) 2022-08-30 2025-09-04 ピノットバイオ インコーポレイテッド カンプトセシン系薬物が抗原結合親和性の低い抗体にリンカーを介して連結された抗体薬物複合体
CR20250432A (es) * 2023-03-28 2025-11-19 Shanghai Hansoh Biomedical Co Ltd Conjugados de ligando-fármaco citotóxico y usos farmacéuticos de estos
WO2025170834A1 (en) * 2024-02-06 2025-08-14 Canget Biotekpharma, Llc Fl118 complexes for targeting ddx5, ube2t or usp2a

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442565B (zh) * 2010-10-29 2016-08-10 健康研究股份有限公司 使用用于癌症治疗的化合物fl118制剂的非水溶性化合物新型制剂及方法
WO2015012904A2 (en) * 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US10206918B2 (en) * 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
JP6427789B2 (ja) * 2013-07-23 2018-11-28 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. Cl2aリンカーを有する抗体−sn−38免疫複合体
SG11201603960XA (en) * 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US10344037B2 (en) * 2014-03-26 2019-07-09 Canget BioTek Pharma LLC Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease
TWI920652B (zh) * 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物

Similar Documents

Publication Publication Date Title
JP2021059564A (ja) 癌治療のための併用療法
JP2016520082A5 (cg-RX-API-DMAC7.html)
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
JP2018527383A5 (cg-RX-API-DMAC7.html)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2013520442A5 (cg-RX-API-DMAC7.html)
JP2014510080A5 (cg-RX-API-DMAC7.html)
JP2019519499A5 (cg-RX-API-DMAC7.html)
JP2015534577A5 (cg-RX-API-DMAC7.html)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
JP2016534039A5 (cg-RX-API-DMAC7.html)
JP2015534578A5 (cg-RX-API-DMAC7.html)
FI3653228T3 (fi) Folr1:n vastaisen immunokonjugaatin annostusohjelmia
JP2011507932A5 (cg-RX-API-DMAC7.html)
JP2014502955A5 (cg-RX-API-DMAC7.html)
JP2020527332A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2019524713A5 (cg-RX-API-DMAC7.html)
JP2018512402A5 (cg-RX-API-DMAC7.html)
RU2657604C2 (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана
CN111065412B (zh) Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
WO2026026912A1 (zh) 抗体药物偶联物和抗vegf抗体的联合应用
RU2021133713A (ru) Adc для лечения сопутствующе с или после доцетаксела